Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818749 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ANPC1PRMT5WDR77 | |
| SCHEMBL2208415 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ANPC1PRMT5WDR77 | |
| SCHEMBL4568834 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ANPC1ACACBMAPT | |
| SCHEMBL16030373 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19291785 | 0.84 | CARM1 (0.43) | ACACB | |
| SCHEMBL19291653 | 0.84 | CARM1 (0.43) | ACACB | |
| SCHEMBL16032232 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL2206380 | 0.83 | SIRT2 (0.43) | — | |
| SCHEMBL19291575 | 0.83 | SIRT2 (0.43) | — | |
| SCHEMBL19291555 | 0.83 | SIRT2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SMN1; SMN2 39/4885RAB9A 2078/4885NPC1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.